SCHEMBL209485

SCHEMBL209485

Cn1cncc1CN1CCNCC1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.41
LMNA P02545 1/20 0.39
CXCR4 P61073 5/20 0.38
MEN1 O00255 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
ADRA2C P18825 1/20 0.38
CCR2 P41597 1/20 0.38
CXCL12 P48061 1/20 0.38
BLM P54132 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
CHRM5 P08912 1/20 0.37
TLR9 Q9NR96 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
MLNR O43193 1/20 0.36
KCNH2 Q12809 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20458924 0.94 CXCR4 (0.47) SIGMAR1LMNACXCR4MEN1CHRM2
SCHEMBL16538615 0.81 CHRM5 (0.38) LMNAMEN1CHRM2CHRM1BLM
SCHEMBL12424288 0.78 ALDH1A1 (0.45) CHRM1HRH3CHRM5TLR9TLR7
SCHEMBL31599664 0.77 KCNH2 (0.34) LMNAMEN1CHRM2CHRM1KMT2A
SCHEMBL15473910 0.77 CHKA (0.49) TDP1
SCHEMBL209789 0.74 MEN1 (0.40) MEN1KMT2ACHRM5MLNR
SCHEMBL12384834 0.74 TLR9 (0.39) LMNAMEN1CHRM2CHRM1BLM
SCHEMBL8307165 0.72 SIGMAR1 (0.53) SIGMAR1CXCR4MEN1KMT2AKCNH2
SCHEMBL18923901 0.72 PIK3CD (0.36) CHRM1CHRM5TLR9TLR7MLNR
SCHEMBL16903851 0.71 SIGMAR1 (0.44) SIGMAR1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017108723-A2 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2017-06-29 WO disclosed
EP-1963315-B1 ENZYME INHIBITORS CANCER REC TECH LTD (GB) 2014-10-08 EP disclosed
US-8088761-B2 Enzyme inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2012-01-03 US disclosed
US-20090247507-A1 Enzyme Inhibitors THE INSTITUTE OF CANCER RESEARCH (GB) 2009-10-01 US disclosed
EP-1963315-A2 ENZYME INHIBITORS The Institute of Cancer Research (GB) 2008-09-03 EP disclosed
WO-2007072017-A2 ENZYME INHIBITORS THE INSTITUTE OF CANCER RESEARCH (GB) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247507-A1 Enzyme Inhibitors AURKC, AURKB, AURKA SIGMAR1 2301/4885LMNA 2674/4885CXCR4 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.